St. Jude Medical, Inc. Exhibit 99.1

St. Paul, Minn. – July 18, 2007 – St. Jude Medical, Inc. (NYSE: STJ) today reported sales and net earnings for the second quarter ended June 30, 2007.

The Company reported net sales of $947 million in the second quarter of 2007, an increase of 14% compared to the $833 million in the second quarter of 2006. Favorable foreign currency translation comparisons increased second quarter sales by approximately $21 million.

Reported net earnings for the second quarter of 2007 were $135 million, or $0.39 per diluted share, which includes a special charge related to the settlement of a patent litigation matter this quarter that reduced earnings by $0.06 per diluted share. This compares to reported net earnings for the second quarter of 2006 of $141 million, or $0.38 per diluted share.

Commenting on the second quarter results, St. Jude Medical Chairman, President and Chief Executive Officer Daniel J. Starks said, “Every major segment of St. Jude Medical’s business contributed growth, market share gains, or both for the third consecutive quarter. Over 75% of our revenue grew at double-digit rates for the second quarter in a row. Due to these results and our strong outlook for the second half of 2007, we are raising our earnings per share guidance for the full-year.”

Total Cardiac Rhythm Management sales, which include implantable cardioverter defibrillator (ICD) and pacemaker products, were $595 million for the second quarter of 2007, a 15% increase compared to the second quarter of 2006.

Of that total, ICD product sales were $327 million in the second quarter, an 18% increase compared to the second quarter of 2006.

Second quarter pacemaker sales were $268 million, an increase of 11% from the comparable quarter of 2006.

AF product sales for the second quarter totaled $100 million, a 25% increase over the second quarter of 2006.

St. Jude Medical sales of neuromodulation products were $52 million in the second quarter of 2007, up 18% from the comparable quarter of 2006.

Total cardiovascular sales, which include primarily vascular closure and heart valve products, were $200 million for the second quarter of 2007, a 5% increase over the second quarter of 2006.

Sales of vascular closure products in the second quarter of 2007 were $89 million, a 2% increase over the second quarter of 2006.

Total heart valve product sales for the second quarter of 2007 were $76 million, a 7% increase over the second quarter of 2006.

During a conference call today, St. Jude Medical will update its range for revenue expectations for the third quarter and the full-year for its product categories.

The Company expects its consolidated earnings for the third quarter of 2007 to be in the range of $0.44 to $0.45 per diluted share and is raising its guidance for consolidated earnings per share for the full-year 2007 to the range of $1.74 to $1.78. This guidance does not include the impact on earnings per share of the special charge recorded in the second quarter of 2007. A further reconciliation of the Company’s annual guidance is provided in the schedule below.

The Company provides adjusted net earnings and adjusted earnings per share because St. Jude Medical management believes that in order to properly understand the Company’s short-term and long-term financial trends, investors may wish to consider the impact of certain adjustments (such as in-process research and development charges, restructuring charges, litigation charges or litigation reserve adjustments and income tax adjustments). These adjustments result from facts and circumstances (such as business development activities, restructuring activities, settlements and other developments relating to litigation and resolution of audits by tax authorities) that vary in frequency and impact on the Company’s results of operations. St. Jude Medical management uses adjusted net earnings and adjusted earnings per share to forecast and evaluate the operational performance of the Company as well as to compare results of current periods to prior periods on a consolidated basis.

Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. Investors should consider non-GAAP measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with GAAP.

St. Jude Medical’s second quarter earnings call can be heard live today beginning at 7:15 a.m. CT (also archived for 90 days) on the following website:

http://phx.corporate-ir.net/phoenix.zhtml?p=eventDetails&c=73836&eventID=1570513.

St. Jude Medical is dedicated to making life better for cardiac, neurological and chronic pain patients worldwide through excellence in medical device technology and services. The Company has five major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiac surgery, cardiology and neuromodulation. Headquartered in St. Paul, Minn., St. Jude Medical employs approximately 12,000 people worldwide. For more information, please visit www.sjm.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings, and market shares. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s filings with the SEC, including those described in the Company’s Annual Report on Form 10-K filed on February 28, 2007 (see pages 13-20) and Quarterly Report on Form 10-Q filed on May 9, 2007 (see pages 23-24). The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.

	Three Months Ended						Six Months Ended
	June 30, 2007			July 1, 2006			June 30, 2007			July 1, 2006
Net sales	$	947,336		$	832,922		$	1,834,314		$	1,617,338
Cost of sales		253,023			226,964			492,000			435,411
Gross profit		694,313			605,958			1,342,314			1,181,927

Selling, general & administrative		348,694			301,022			677,034			585,230
Research & development		119,458			108,840			235,416			214,098
Special charge		35,000			0			35,000			0

Operating profit		191,161			196,096			394,864			382,599
Other income (expense)		(10,450	)		(5,219	)		(15,618	)		(5,923	)
Earnings before taxes		180,711			190,877			379,246			376,676
Income tax expense		45,911			49,845			98,721			98,575
Net earnings	$	134,800		$	141,032		$	280,525		$	278,101

Adjusted net earnings (Non-GAAP)	$	156,675	(1)				$	302,400	(1)

Diluted net earnings per share	$	0.39		$	0.38		$	0.79		$	0.73
Adjusted diluted net earnings per share (Non-GAAP)	$	0.45	(1)				$	0.85	(1)

Weighted average shares outstanding-diluted		349,567			375,141			354,422			380,069

	June 30, 2007		December 30, 2006
Cash & cash equivalents	$	108,261	$	79,888
Accounts receivable, net		947,529		882,098
Inventories		493,394		452,812
Other current assets		323,477		275,367
Property, plant & equipment, net		684,322		617,851
Goodwill		1,648,930		1,649,581
Other intangible assets, net		542,455		560,276
Other assets		301,413		271,921
Total assets	$	5,049,781	$	4,789,794

Current liabilities		578,516		676,207
Long-term debt		1,656,862		859,376
Deferred income taxes, net		128,027		163,336
Long-term other liabilities		238,603		121,888
Total equity		2,447,773		2,968,987
Total liabilities & equity	$	5,049,781	$	4,789,794

Estimated 2007 diluted net earnings per share		$1.68 - $1.72
Estimated 2007 adjusted diluted net earnings per share (Non-GAAP)		$1.74 - $1.78	(2)